In a recently published in-vitro study by researchers at Doctor’s Biome, their medical food resulted in complete inhibition of epsilon toxin-producing Clostridium perfringens.
Doctor’s Biome is a liquid probiotic supplement that contains 15 strains of living probiotics in a fully organic fruit and vegetable juice blend.
The medical food is intended for the dietary management of Multiple Sclerosis (MS), the most common neurological disease in young adults.
Doctor’s Biome CEO Richard Finkelstein said: “In our previous press release about Doctor’s Biome Women’s Health dietary supplement, I promised that as we are continuing our path, I will announce more novel products in a near future. I kept my promise.
“Today, I am excited to announce that development of our patent-pending pioneering Medical Food for people with Multiple Sclerosis is complete.
“It is a good feeling to see the mission we have chosen for the company “Be the Leader in Juice-Based Clinically Validated Probiotics is achievable.”
According to the company, only nine FDA-approved oral medications are currently available for MS, and each drug has its own unwanted side effects.
The underlying cause of MS is not known, but Clostridium perfringens, a gut bacterium that produces epsilon toxin is believed to be its trigger.
Doctor’s Biome said that the gut bacterium can be managed through dietary interventions.
However, no specific dietary supplement or medical food has been available for this purpose.
The medical food is manufactured with 60 billion colony-forming units (CFU) of unique Doctor’s Biome signature probiotic blend (DBSPB) in sterilised organic green fruit and vegetable juice.
The company uses Two strains of epsilon toxin-producing C. perfringens, ATCC 3626 (type B) and ATCC 3631 (type D), as the target pathogenic microorganisms.
It is the first study of pre-hydrated probiotics in a sterilised liquid juice medium, which has inhibited type B and type D epsilon toxin-producing C. perfringens, said the company.
Doctor’s Biome chief science and technology officer Reza Kamarei said: “We are delighted that we have developed a patent-pending juice-based probiotic medical food for the dietary management of MS that inhibits the growth of both type B and type D epsilon toxin-producing Clostridium perfringens.
“This would have not been possible without the valuable contributions and cooperations of Dr. Howard Robins.”
